JP2023546742A5 - - Google Patents

Info

Publication number
JP2023546742A5
JP2023546742A5 JP2023548994A JP2023548994A JP2023546742A5 JP 2023546742 A5 JP2023546742 A5 JP 2023546742A5 JP 2023548994 A JP2023548994 A JP 2023548994A JP 2023548994 A JP2023548994 A JP 2023548994A JP 2023546742 A5 JP2023546742 A5 JP 2023546742A5
Authority
JP
Japan
Prior art keywords
group
independently selected
alkyl
substituted
appropriately substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023548994A
Other languages
English (en)
Japanese (ja)
Other versions
JP7882861B2 (ja
JP2023546742A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/125409 external-priority patent/WO2022083703A1/en
Publication of JP2023546742A publication Critical patent/JP2023546742A/ja
Publication of JP2023546742A5 publication Critical patent/JP2023546742A5/ja
Application granted granted Critical
Publication of JP7882861B2 publication Critical patent/JP7882861B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023548994A 2020-10-22 2021-10-21 Lpa受容体活性に付随する症状を治療するための化合物および組成物 Active JP7882861B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2020122794 2020-10-22
CNPCT/CN2020/122794 2020-10-22
CN2021113042 2021-08-17
CNPCT/CN2021/113042 2021-08-17
CNPCT/CN2021/122851 2021-10-09
CN2021122851 2021-10-09
PCT/CN2021/125409 WO2022083703A1 (en) 2020-10-22 2021-10-21 Compounds and compositions for treating conditions associated with lpa receptor activity

Publications (3)

Publication Number Publication Date
JP2023546742A JP2023546742A (ja) 2023-11-07
JP2023546742A5 true JP2023546742A5 (cg-RX-API-DMAC10.html) 2024-10-29
JP7882861B2 JP7882861B2 (ja) 2026-06-30

Family

ID=78516438

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548994A Active JP7882861B2 (ja) 2020-10-22 2021-10-21 Lpa受容体活性に付随する症状を治療するための化合物および組成物

Country Status (7)

Country Link
US (1) US20240018102A1 (cg-RX-API-DMAC10.html)
EP (2) EP4232431B1 (cg-RX-API-DMAC10.html)
JP (1) JP7882861B2 (cg-RX-API-DMAC10.html)
CN (1) CN116583501A (cg-RX-API-DMAC10.html)
ES (1) ES3049795T3 (cg-RX-API-DMAC10.html)
TW (1) TW202233575A (cg-RX-API-DMAC10.html)
WO (1) WO2022083703A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024540937A (ja) * 2021-10-21 2024-11-06 ローツェ・バイオ・インコーポレイテッド Lpa受容体活性に関連する状態を処置するための化合物および組成物
TW202342017A (zh) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與lpa受體活性相關的病狀的化合物及組合物
WO2026002179A1 (en) * 2024-06-28 2026-01-02 Rezubio Pharmaceuticals Co., Ltd Compounds and compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1553075B1 (en) * 2002-10-03 2013-08-14 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonists
TW200521108A (en) * 2003-12-19 2005-07-01 Ono Pharmaceutical Co Compounds having lysophosphatidic acid receptor(LPA)-antagonizing effect and their use
CN101119714A (zh) * 2005-02-14 2008-02-06 弗吉尼亚大学专利基金会 含有由氨基和苯基取代的环烷基和5元杂环的1-磷酸鞘氨醇激动剂
EP2744807A4 (en) * 2011-08-15 2015-03-04 Intermune Inc COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS
AR108838A1 (es) * 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
CN111712492B (zh) * 2017-12-19 2024-05-31 百时美施贵宝公司 作为lpa拮抗剂的环己基酸三唑唑类
US11447475B2 (en) * 2017-12-19 2022-09-20 Bristol-Myers Squibb Company Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists

Similar Documents

Publication Publication Date Title
HRP20241159T1 (hr) Heterociklički agonisti za glp-1
JP2024522373A5 (cg-RX-API-DMAC10.html)
JP2021508686A5 (cg-RX-API-DMAC10.html)
TW202039470A (zh) 一種THRβ受體激動劑化合物及其製備方法和用途
RU2415856C2 (ru) ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ ТЕТРАГИДРОПИРОЛЛО[3,2-c]ПИРИДИН-4-ОНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ ОЖИРЕНИЯ, ПСИХИАТРИЧЕСКИХ И НЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ
JP2022512482A5 (cg-RX-API-DMAC10.html)
RU2012103487A (ru) Ингибирующие jak соединения на основе пиразолопиримидина и способы
JP6407955B2 (ja) クマリン誘導体、ならびに過剰増殖疾患を治療する際の使用方法
JP2022544714A5 (cg-RX-API-DMAC10.html)
JP2019510787A5 (cg-RX-API-DMAC10.html)
JP2023544476A5 (cg-RX-API-DMAC10.html)
JP2021529814A5 (cg-RX-API-DMAC10.html)
JPH07502742A (ja) Paf−レセプタ拮抗剤としてのアミノ酸誘導体
JP2010540508A5 (cg-RX-API-DMAC10.html)
JP2023552610A (ja) 新規カンプトテシン誘導体、それを含む組成物およびその使用
JP2022519131A5 (cg-RX-API-DMAC10.html)
JP2024534840A5 (cg-RX-API-DMAC10.html)
JP2022529371A5 (cg-RX-API-DMAC10.html)
WO2022100624A1 (zh) 氧取代氨基碳酸酯噻吩类化合物及其用途
JP2007515419A5 (cg-RX-API-DMAC10.html)
JP2023516714A (ja) 新規ep4拮抗薬の合成及びその癌及び炎症における使用
WO2019109415A1 (zh) 一种靶向降解hmgcr的化合物及其应用
JP2024502473A5 (cg-RX-API-DMAC10.html)
JPH01250372A (ja) ジ‐tert‐ブチルフェノール化合物の環状抗炎症性誘導体
AU2019228915A1 (en) 4-methyldihydropyrimidinone compound and medicinal use thereof